8-KEarnings & ResultsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Feb 7, 2019)

Filed February 7, 2019For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on February 7, 2019, primarily to announce its financial results for the fourth quarter and full year ended December 31, 2018. While the 8-K itself does not contain the detailed financial data, it references a press release (Exhibit 99.1) which provides these results. Investors should refer to this press release for specific figures regarding revenue, expenses, net income/loss, and any forward-looking guidance issued by the company. This filing is crucial for understanding Alnylam's financial performance leading into 2019. Key areas of interest for investors would be the progress of their drug pipeline, revenue generation from existing products (if any), and the company's overall financial health. The press release accompanying this 8-K is the primary source of actionable financial information for shareholders and potential investors.

Key Highlights

  • 1Alnylam Pharmaceuticals announced its Q4 and Full Year 2018 financial results on February 7, 2019.
  • 2The detailed financial results are provided in an accompanying press release, furnished as Exhibit 99.1 to the 8-K.
  • 3The 8-K filing itself serves as notification and filing of the press release containing the financial results.
  • 4Investors should consult the furnished press release for specific financial performance data and operational updates.
  • 5The filing is for the period ended December 31, 2018.
  • 6The company's Chief Financial Officer, Manmeet S. Soni, signed the filing.

Frequently Asked Questions

The actual financial results are detailed in the press release furnished as Exhibit 99.1 to this 8-K filing. You should refer to that document for specific revenue, earnings, and other financial metrics.

This 8-K filing is significant because it officially announces Alnylam's financial performance for the fourth quarter and full year of 2018. It directs investors to the press release which contains the critical financial data and potentially company updates.

The 8-K filing itself typically does not contain detailed forward-looking guidance. This information would be found within the press release (Exhibit 99.1) that is referenced in the filing.

No, the information furnished under Item 2.02 of this 8-K, including the press release, is not deemed 'filed' for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, unless specifically incorporated by reference into another filing.